Result of AGM
Updated : 18:05
Oxford Biomedica
Result of Annual General Meeting
Oxford, UK - 27 May 2022: Oxford Biomedica plc (LSE:OXB) ("Oxford Biomedica" or "the Company"), a leading gene and cell therapy group, announces today that all resolutions proposed were duly passed at its Annual General Meeting (AGM), held at 3pm on 27 May 2022 in Oxford. As proposed in the Notice of AGM, all resolutions were decided by poll vote.
The full text of all the resolutions can be viewed in the Notice of Meeting by visiting the Company's website at www.oxb.com
Copies of the document setting out the above resolutions passed at the 2022 AGM have been submitted to the National Storage Mechanism and will shortly be available for inspection at: https://data.fca.org.uk/#/nsm/nationalstoragemechanism
On the Record Date (25 May 2022) there were 96,063,479 ordinary shares of 50 pence each in issue, each carrying one vote per share.
|
Resolution |
Votes For (incl. votes at the Chairman's discretion) | Votes at other proxy Discretion |
Votes Against |
Votes Withheld* |
Total votes cast | Result |
|
|
|
|
|
|
|
|
| Ordinary resolutions | ||||||
1
| To receive the Company's Accounts, the Reports of the Directors and Auditor and the Strategic Report for the year ended 31 December 2021. | 71,533,247 (99.99%)
| 0 | 3,804 (0.01%)
| 907,786
| 71,537,051
| Passed
|
2
| To receive the Directors' Remuneration Report and the Report of the Auditor on the Remuneration Report for the year ended 31 December 2021. | 57,808,878 (80.73%)
| 0 | 13,801,220 (19.27%)
| 834,739
| 71,610,098
| Passed
|
3
| To appoint Dr. Michael Hayden as a Director. | 62,539,719 (87.06%)
| 0 | 9,295,954 (12.94%)
| 609,164
| 71,835,673
| Passed
|
4
| To appoint Catherine Moukheibir as a Director. | 71,748,494 (99.88%)
| 0 | 86,921 (0.12%)
| 609,422
| 71,835,415
| Passed
|
5
| To appoint Namrata P. Patel as a Director. | 71,746,512 (99.88%)
| 0 | 88,903 (0.12%)
| 609,422
| 71,835,415
| Passed
|
6
| To reappoint Dr. Roch Doliveux as a Director. | 68,788,280 (96.81%)
| 0 | 2,264,491 (3.19%)
| 1,392,066
| 71,052,771
| Passed
|
7
| To reappoint Professor Dame Kay Davies as a Director. | 69,259,453 (96.41%)
| 0 | 2,575,962 (3.59%)
| 609,422
| 71,835,415
| Passed
|
8
| To reappoint Dr. Siyamak Rasty as a Director. | 71,719,604 (99.84%)
| 0 | 116,069 (0.16%)
| 609,164
| 71,835,673
| Passed
|
9
| To reappoint Stuart Paynter as a Director. | 71,206,012 (99.12%)
| 0 | 629,661 (0.88%)
| 609,164
| 71,835,673
| Passed
|
10
| To reappoint Stuart Henderson as a Director. | 67,003,486 (93.27%)
| 0 | 4,832,187 (6.73%)
| 609,164
| 71,835,673
| Passed
|
11
| To reappoint Dr. Heather Preston as a Director | 64,708,975 (90.08%)
| 0 | 7,126,698 (9.92%)
| 609,164
| 71,835,673
| Passed
|
12
| To reappoint Robert Ghenchev as a Director. | 71,526,110 (99.57%)
| 0 | 309,305 (0.43%)
| 609,422
| 71,835,415
| Passed
|
13
| To reappoint KMPG LLP as auditor. | 71,831,890 (99.99%)
| 0
| 7,494 (0.01%)
| 605,453
| 71,839,384
| Passed
|
14
| To authorise the Directors to agree the remuneration of the auditor. | 71,832,849 (99.99%)
| 0
| 6,921 (0.01%)
| 605,067
| 71,839,770
| Passed
|
15
| To authorise the Directors to allot shares. | 67,355,882 (93.77%)
| 0
| 4,471,767 (6.23%)
| 617,188
| 71,827,649
| Passed
|
|
Special resolutions | ||||||
16
| To authorise the Directors to disapply pre-emption rights. | 70,888,310 (98.70%)
| 0 | 937,061 (1.30%)
| 619,466
| 71,825,371
| Passed
|
17
| To authorise the Directors to further disapply pre-emption rights for acquisitions and specified capital investments. | 70,922,796 (98.74%)
| 0 | 903,407 (1.26%)
| 618,634
| 71,826,203
| Passed
|
18
| To permit the Directors to convene general meetings (other than annual general meetings) on not less than 14 days' notice. | 69,350,429 (96.53%) | 0 | 2,489,321 (3.47%) | 605,087 | 71,839,750
| Passed
|
* A vote withheld is not a vote in law and is not counted towards votes cast in respect of a resolution.
In addition, further to the announcements by the Company in January and April, John Dawson has stepped down from the Company's Board of Directors after more than thirteen years of service with effect from the conclusion of today's AGM.
-Ends-
Enquiries:
Oxford Biomedica plc: T: +44 (0)1865 783 000 / E: ir@oxb.com |
Stuart Paynter, Chief Financial Officer Sophia Bolhassan, Head of Investor Relations |
Consilium Strategic Communications: T: +44 (0)20 3709 5700 / E: oxfordbiomedica@consilium-comms.com
Mary-Jane Elliott / Matthew Neal / Matthew Cole |
About Oxford Biomedica
Oxford Biomedica (LSE:OXB) is an innovative leading viral vector specialist focused on delivering life changing therapies to patients.
Oxford Biomedica plc and its subsidiaries (the Group) work across key viral vector delivery systems including those based on lentivirus, adeno-associated virus (AAV) and adenovirus, providing innovative solutions to cell and gene therapy biotechnology and biopharma companies for their process development, analytical development and manufacturing needs. Oxford Biomedica has built a sector leading lentiviral vector delivery system, LentiVector® platform, which the Group leverages to develop product candidates in-house, before seeking partners to take the products into clinical trials.
Oxford Biomedica is based across several locations and headquartered in Oxfordshire, UK. In early 2022, the Group established Oxford Biomedica Solutions, a new US based subsidiary AAV manufacturing and innovation business, based near Boston, US.
Oxford Biomedica employs more than 940 people. Further information is available at www.oxb.com.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.